The global synthetic biology market size is expected to reach USD 42.06 billion by 2030, registering a CAGR of 17.30% 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of government and private funding to support research in vaccines and a strong synthetic biologic-based product pipeline in clinical trials are the key driving factors for the market. Synthetic biology processes provide crucial advantages for producing antigen and diagnostic reagents for disease identification, accelerating the speed of vaccine development, and improving overall vaccine performance and yield.
Furthermore, support from government agencies and the presence of several programs are likely to boost the market growth. For instance, in the U.S., COVID-19 vaccine R&D, manufacture, regulation, and purchase have been highly supported by collaboration between federal agencies, including the Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH), DOD, FDA, and others (formerly OWS).
Other factors such as expanding demand in industries such as textiles and nutrition are also contributing to the market growth. Several optimal food production processes have been identified with the help of synthetic biology. In addition, synthetic biology is predicted to aid in the generation of higher agricultural yields and pest control development. It is expected to help in the production of better food yield and pest control management.
The COVID-19 pandemic is anticipated to positively impact market growth. Synthetic biology has been highlighted as a means to accelerate vaccine development by the National Institute of Health in the U.S. Therefore, synthetic biology labs and companies have been actively utilizing this technology to combat the COVID-19 pandemic. As a result, the usage of these technologies is projected to increase during the outbreak.
The growing demand for personalized medicine is expected to majorly drive market growth during the coming years. The use of engineered novel proteins for use as therapeutics has demonstrated synthetic biology in the medical segment. These proteins are designed with some modified protein structure to get the desirable properties required for the treatment. For instance, researchers are developing a therapeutic enzyme candidate that is GI-stable and can be given via oral route to treat Phenylketonuria (PKU).
On the other hand, synthetic biology has raised a few concerns regarding biosecurity and biosafety. Exposure to these products may cause unknown hazards to public health and the environment. To prevent such issues, countries of Europe, the Americas, and Asia have formulated policies to manage the application of synthetic biology techniques in basic & applied research.
Request a free sample copy or view report summary: Synthetic Biology Market Report
By technology, the PCR segment held the largest share of the market. This is attributed to the accelerated development in modern life science, with PCR technology being widely employed in numerous fields of medical research, virus detection, and the food & beverage industry
The genome-editing segment is expected to grow steadily during the forecast period. It enables researchers to modify the DNA of various organisms, including plants, bacteria, and animals, and their demand is expected to skyrocket in the coming years
By product, Oligonucleotide and Synthetic DNA is anticipated to have the larger market share in 2030. The falling price of synthesis and increasing requirement for synthetic DNA, RNA, and genes that are employed in numerous applications contribute to the segment growth
By application, the healthcare segment held a larger global market share. This is attributed to an increase in drug screening and discovery. Moreover, the use of synthetic biology can reduce the cost of drug discovery and propel market growth
By end-user, the biotechnology and pharmaceutical companies segment held a larger share in 2024, owing to the growing availability of modern research facilities, favorable legislation, and government assistance and funding
North America was positioned as the dominant market in 2024 due to the presence of high R&D investment, the availability of technologically advanced healthcare research frameworks, and the development of the synthetic biology market in the region
The Asia Pacific is expected to witness considerable growth in the future owing to the rising development of personalized treatment and the presence of key players
Grand View Research has segmented the global synthetic biology market based on product, technology, application, end use, and region
Synthetic Biology Product Outlook (Revenue, USD Million, 2018 - 2030)
Oligonucleotide/Oligo Pools and Synthetic DNA
Enzymes
Cloning Technologies Kits
Xeno-Nucleic Acids
Chassis Organism
Synthetic Biology Technology Outlook (Revenue, USD Million, 2018 - 2030)
NGS Technology
PCR Technology
Genome Editing Technology
Bioprocessing Technology
Other Technologies
Synthetic Biology Application Outlook (Revenue, USD Million, 2018 - 2030)
Healthcare
Clinical
Bio/Pharmaceuticals
Diagnostics
Non-Clinical
Non-healthcare
Biotech Crops
Specialty Chemicals
Bio-fuels
Others
Synthetic Biology End Use Outlook (Revenue, USD Million, 2018 - 2030)
Biotechnology and Pharmaceutical companies
Academic and Research Institutes
Others
Synthetic Biology Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Synthetic Biology Market
Bota Biosciences Inc.
Codexis, Inc.
Creative Biogene.
Creative Enzymes.
Enbiotix, Inc.
Illumina, Inc.
Merck Kgaa (Sigma-Aldrich Co. Llc)
New England Biolabs
Eurofins Scientific
Novozymes
Pareto Bio, Inc.
Scarab Genomics, Llc
Synthego
Synthetic Genomics Inc.
Thermo Fisher Scientific, Inc.
"The quality of research they have done for us has been excellent..."